Hikma acquires Novugen's FDA-approved ANDA for trametinib
Go back to Hikma acquires Novugen's FDA-approved ANDA for trametinib| Hikma Pharmaceuticals plc, London Sponsored ADR (AMEX: HKMPY) | Delayed: 43.18 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $43.18 | 52 Week High | $76.47 | |||
| Open | $43.18 | 52 Week Low | $50.73 | |||
| Day High | $43.18 | P/E | N/A | |||
| Day Low | $43.18 | EPS | $0.00 | |||
| Volume | 29,725 | |||||
